1-2 of 2
Wen-Jiang Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma

Cha Len Lee, Grainne M. O'Kane, Warren P. Mason, Wen-Jiang Zhang, Pavlina Spiliopoulou, Aaron R. Hansen, Robert C. Grant, Jennifer J. Knox, Tracy L. Stockley, Gelareh Zadeh, Eric X. Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 394–399.
https://doi.org/10.1158/1535-7163.MCT-23-0460
Published: 04 March 2024
View articletitled, Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma in another window
Journal Articles

Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.

Albiruni RA Razak, Philippe L. Bedard, Benoit You, Devang Panchal, Eric X. Chen, S. Percy Ivy, Wen-Jiang Zhang, Suzanne Kamel-Reid, Nhu-An Pham, Tong Zhang, Sebastien J. Hotte, Michael Reedijk, Momiko Shimizu, Laurie Ailles, Christine Haines, Amit Oza, Ming Tsao, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B50.
https://doi.org/10.1158/1535-7163.TARG-11-B50
Published: 12 November 2011
View articletitled, Abstract B50: A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.